Romosozumab as a Safe Bone-Forming Treatment for Elderly Patients with Established Cardiovascular Risk Factors
Poster presentation: POS 0341
Date: Sunday, 26th October 2025
Presenting author: D. Ramos Castro (Spain)
This study evaluated romosozumab safety in elderly osteoporosis patients with cardiovascular risk factors. Forty-nine patients were included; 75.5% had primary osteoporosis, 70.2% had prior fractures. Main cardiovascular risk factors were dyslipidemia (42.9%), hypertension (40.8%), diabetes (8.2%). Mean treatment duration was 10.51 months. No major cardiovascular adverse event happened. Twenty-eight patients completed the 12-month course. β-CTX decreased (0.33→0.23), ALP decreased (100.12→80.85), P1NP increased (47.94→58.18). BMD increased at all sites, reducing osteoporosis proportion from 70.45% to 45.67% at lumbar spine.
JAK Inhibitors and Bone Health in Rheumatoid Arthritis and Psoriatic Arthritis: A Real-World Cohort Analysis
Oral presentation: OP 0343
Date: Sunday, 26th October 2025
Presenting author: E. Wiebe (Germany)
This study quantified the impact of JAK inhibitors on bone health in a real-world cohort of patients with RA and PsA from the Rh-GIOP study. 856 patients (mean age 64 years, 77% female, 92% postmenopausal) were included, with 89 receiving JAK inhibitors. Bone health was assessed using DXA for BMD, trabecular bone score (TBS), and 3D structural parameters. Vertebral trabecular microarchitecture expressed by TBS showed that JAK inhibition was positively associated with TBS suggesting a potential positive impact on trabecular microarchitecture.
Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis
Poster presentation: POS 0319
Date: Sunday, 26th October 2025
Presenting author: D. Madison (Florida, USA)
This meta-analysis evaluated GLP-1RAs in knee osteoarthritis management, including two studies: STEP 9 and Shanghai Osteoarthritis Cohort. GLP-1RA therapy led to a pooled reduction in body weight of -9.70 kg. For WOMAC pain score, the pooled mean difference was -0.49 points, reflecting symptom improvement. Physical function demonstrated a pooled SMD of -1.29. For total WOMAC score, pooled SMD was -0.30, and for stiffness, SMD was -0.23. Despite variable heterogeneity, benefit consistently favored GLP-1RAs. GLP-1RAs appear to reduce pain in KOA patients.
Acute Transcriptomic Response of Synovium and Dorsal Root Ganglia to Joint Injury
Poster presentation: POS 1739
Date: Tuesday, 28th October 2025
Presenting author: M. Newton (Illinois, USA)
This study investigated synovium-nerve signaling following ACL rupture using bulk RNA sequencing in mice. Under IACUC approval, 12-week-old male C57Bl/6 mice underwent ACL rupture or sham procedure (n=6). At 1, 3, or 7 days post-injury, RNA was isolated from ipsilateral synovium and L3-L5 DRGs for bulk RNA sequencing. Quality control confirmed high RNA and sequencing quality with high DRG neuronal enrichment. The study aimed to elucidate the acute transcriptomic response underpinning injury-induced nociceptor sprouting.
Endocrine-Disrupting Chemicals Amplify Osteoarthritis Pain and Inflammatory Responses in a Sex-Specific Manner
Oral presentation: OP 1735
Date: Tuesday, 28th October 2025
Presenting author: E. Herardot (France)
This study investigated whether low-dose exposure to 14 endocrine-disrupting chemicals (EDCs) modulates OA severity and pain in mice. Male and female C57BL/6 mice were exposed locally via intra-articular injections or systemically through drinking water from in utero. In male mice, local EDC exposure significantly increased OA-related pain over 21 days, reduced physical activity, and worsened synovitis and cartilage damage. Female mice showed reduced activity but no mechanical hypersensitivity. This reveals EDCs amplify OA pain and inflammation in a sex-specific manner.
Traction Therapy May Improve Hand Function in Those with Distal Interphalangeal Osteoarthritis
Poster presentation: POS 2089
Date: Tuesday, 28th October 2025
Presenting author: G. Lo (NY, USA)
This multi-center, double-blind trial evaluated traction therapy for DIP osteoarthritis. Thirty-three participants were randomized to traction device plus standard care versus standard care alone. Patients were evaluated at baseline and weeks 4, 12, and 24. DASH scores were significantly better in the traction arm by 11 points, and Michigan Hand Outcome ADLs scores were better by 12 points. This study suggests function may improve in the treatment arm. Functional assessments may be better outcome measures than pain for hand OA interventions.
Development of a Fracture Prediction Model for Patients Aging with HIV
Poster presentation, POS 2114
Date: Tuesday, 28th October 2025
Presenting author: E. Hsieh (Connecticut, USA)
This study developed predictive models for fragility fracture risk in people aging with HIV (PAH). Using data from the Veterans Aging Cohort Study, all PAH (≥50 years) were followed from 2009-2019. The cohort included 32,842 individuals contributing 223,607 person-years. From 27 candidate predictors, multivariable logistic regression identified 10 predictors for one-year and three-year models including age, albumin, alcohol use, chronic medication count, BMI, fall history, COPD, female sex, prior fracture, and nonwhite race. One-year and three-year models exhibited good discrimination with AUC.
Claudia Iannone
Claudia is a Rheumatology resident at Milan University, carrying out her research at Gaetano-Pini Hospital in Milan, Italy.
Her research interests are focused systemic sclerosis, Interstital lung disease in rheumatic diseases and vasculitis.
She is a member of the Italian Society of Rheumatology of EULAR lung study group and of EUSTAR YIG.
Claudia is part of the social media subcommittee.